Michael joined Foresite Capital in 2016 and is active in the firm’s public and private market investments.
Michael has experience investing across diverse therapeutic areas, including oncology, autoimmune, and infectious diseases. Prior to Foresite Capital, he was an equity analyst at DAFNA Capital Management, a long-short healthcare hedge fund specializing in managing portfolios in public biotech and medical device companies. At DAFNA, Michael analyzed new and current fund positions in addition to formulating investment ideas in small/mid-cap biotechnology companies.
Michael previously worked in early stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his Ph.D. in Biochemistry from Caltech, where he was awarded an NSF graduate research fellowship, and his B.S. in Molecular, Cell and Developmental Biology from UCLA. He has more than 12 years of experience as a research scientist and has authored numerous publications in top-tier biomedical research journals.